DOCSLIB.ORG

Polysaccharide Structure Dictates Mechanism of Adaptive Immune Response to Glycoconjugate Vaccines

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Polysaccharide Structure Dictates Mechanism of Adaptive Immune Response to Glycoconjugate Vaccines Polysaccharide structure dictates mechanism of adaptive immune response to glycoconjugate vaccines Ximei Suna,b, Giuseppe Stefanettia,c, Francesco Bertid, and Dennis L. Kaspera,1 aDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115; bGraduate Program in Immunology, Harvard Medical School, Boston, MA 02115; cDepartment of Chemistry, University of Milan, 20133 Milan, Italy; and dTechnical R&D, GSK Vaccines, 53100 Siena, Italy Contributed by Dennis L. Kasper, November 1, 2018 (sent for review September 25, 2018; reviewed by Peter R. Andreana and Moriya Tsuji) Glycoconjugate vaccines are among the most effective interven- peptide from the carrier (5). These surface-presented CPSs are + tions for preventing several serious infectious diseases. Covalent able to activate a subset of CD4 T cells, designated carbohydrate- linkage of the bacterial capsular polysaccharide to a carrier protein + specific T cells (Tcarbs), which regulate the adaptive immune provides CD4 T cells with epitopes that facilitate a memory re- response to the GBSIII glycoconjugate (5–8). Similar mechanisms sponse to the polysaccharide. Classically, the mechanism responsi- have now been shown to be responsible for T helper responses to ble for antigen processing was thought to be similar to what was glycoconjugates made with the type 3 S. pneumoniae poly- known for hapten-carrier conjugates: protease digestion of the carrier protein in the endosome and presentation of a resulting saccharide (Pn3P) (6). + peptide to the T cell receptor on classical peptide-recognizing CD4 In the present study, we analyze the T cell response to gly- T cells. Recently, an alternative mechanism has been shown to be coconjugates of several other important pathogens, including responsible for the memory response to some glycoconjugates. Pro- conjugates made from Vi antigen of Salmonella Typhi (Vi), the cessing of both the protein and the polysaccharide creates glycopep- CPS of type Ib group B streptococci (GBSIb), the CPS of H. tides in the endosome of antigen-presenting cells. For presentation, influenzae type b (Hib), and the group C polysaccharide of N. the peptide portion of the glycopeptide is bound to MHCII, allowing meningitidis (MenC). We report that only MenC-specific IgG the covalently linked glycan to activate carbohydrate-specific helper + responses are not regulated by Tcarbs. This lack of Tcarb acti- CD4 T cells (Tcarbs). Herein, we assessed whether this same mech- vation is related to the structure of the polysaccharide. De- anism applies to conjugates prepared from other capsular polysac- INFLAMMATION polymerization of MenC polysaccharide in the acidic environment IMMUNOLOGY AND charides. All of the glycoconjugates tested induced Tcarb-dependent of the endolysosome results in marked reduction in polysaccha- responses except that made with group C Neisseria meningitidis;in the latter case, only peptides generated from the carrier protein ride size to monomers, with a consequent failure to be recognized were critical for helper T cell recognition. Digestion of this acid- by T cells as an independent antigen. Given that there may be sensitive polysaccharide, a linear homopolymer of α(2 → 9)-linked at least two mechanisms governing T cell responses to glyco- sialic acid, to the size of the monomeric unit resulted in a dominant conjugates, a deeper understanding of factors influencing anti- + CD4 T cell response to peptides in the context of MHCII. Our results gen processing and presentation as well as cooperation between show that different mechanisms of presentation, based on the struc- T and B cells in response to glycoconjugate vaccination is a key ture of the carbohydrate, are operative in response to different factor to be considered in improving the design of the next- glycoconjugate vaccines. generation glycoconjugate vaccines. glycoconjugate | vaccine | Tcarb | antigen presentation | group C Neisseria meningitidis Significance any pathogenic bacteria express large-molecular-sized Helper T cell responses to glycoconjugate vaccines are regu- Msurface carbohydrates called capsular polysaccharides lated through mechanisms dependent upon the structure of (CPSs). Beginning in the 1980s, CPSs of bacterial targets were the polysaccharide. We show that three of the four important coupled to carrier proteins to create effective glycoconjugate conjugate vaccines tested induced antibody responses regulated vaccines. These vaccines were more immunogenic than un- primarily by carbohydrate-recognizing helper T cells. However, conjugated polysaccharides, especially in children under 2 y of the adaptive immune response to meningococcal group C (MenC) conjugate was restricted to peptide-recognizing helper T cells. age (1). Several glycoconjugate vaccines were developed and We show that MenC is degraded to a monomeric sialic acid res- have played an enormous role in preventing infectious dis- idue that cannot be recognized by T cell receptor as an inde- eases caused by virulent pathogens, including vaccines against pendent antigen. The structure of the saccharide constitutes a Haemophilus influenzae type b, Streptococcus pneumoniae, and critical factor in determining the processing and presentation of Neisseria meningitidis (2, 3). On the basis of studies of hapten- glycoconjugate vaccines. An understanding of the mechanisms carrier immune responses, it had been assumed that, in glyco- underlying the immune responses to glycoconjugates will be conjugate vaccines, the peptide processed from the carrier pro- crucial in the production of highly protective knowledge-based tein is presented by the major histocompatibility class II vaccines. (MHCII) molecule and that this signal plays a central role in + activating CD4 helper T cells. The peptide-recognizing T cells Author contributions: X.S. and D.L.K. designed research; X.S. performed research; G.S. and in turn help B cell maturation and the formation of immuno- F.B. contributed new reagents/analytic tools; X.S. and D.L.K. analyzed data; and X.S., G.S., logicmemory(4).Theoriginalhypothesis was in part based F.B., and D.L.K. wrote the paper. on the failure of pure polysaccharides to elicit IgM-to-IgG Reviewers: P.R.A., University of Toledo; and M.T., Aaron Diamond AIDS Research Center. class switching and substantial memory responses. Recently, we The authors declare no conflict of interest. reported a different mechanism governing the immune responses Published under the PNAS license. to glycoconjugate vaccines, using the CPS of type III group B 1To whom correspondence should be addressed. Email: [email protected]. Streptococcus (GBSIII) as a model antigen. We showed that This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. antigenic fragments of the polysaccharide are presented on the 1073/pnas.1816401115/-/DCSupplemental. surface by MHCII molecules in the context of a covalently linked www.pnas.org/cgi/doi/10.1073/pnas.1816401115 PNAS Latest Articles | 1of6 Downloaded by guest on October 2, 2021 Results Various Glycoconjugates Induce T Helper Cells Recognizing Different Epitopes. We had previously shown that a clear biomarker for Tcarb-dependent responses was a polysaccharide-specific anti- body response after priming with a polysaccharide covalently linked to a carrier protein and boosting with the same poly- saccharide linked to a different and unrelated carrier protein. To investigate the involvement of Tcarbs in the humoral immune response to different glycoconjugates, we performed priming and boosting immunization experiments with glycoconjugates made with Vi, GBSIb, Hib, and MenC CPSs. BALB/c mice were primed at the beginning of the experiment and boosted 14 d later with different antigen combinations. One week after the boost, serum levels of polysaccharide-specific IgG were determined. For Vi, GBSIb, and Hib glycoconjugates, boosting with a gly- coconjugate containing the same polysaccharide but a heterolo- gous carrier protein induced polysaccharide-specific IgG titers of the same magnitude as those seen after priming and boosting with glycoconjugates containing the same carrier (Fig. 1A). As reported with GBSIII and Pn3P (5, 6), this result supports a Tcarb- dependent mechanism for all three of these glycoconjugates. In marked contrast to the above results, priming and boosting with MenC glycoconjugates containing heterologous carrier proteins induced significantly lower levels of MenC-specific IgG than did primary and secondary immunization with either a MenC-OVA (ovalbumin) conjugate or a MenC-CRM197 (non- toxic mutant of diphtheria toxin) conjugate. This result was confirmed with a combination of different carriers, including MenC-TT (tetanus toxoid), MenC-HEL (hen egg lysozyme), MenC-OVA, and MenC-CRM197 (Fig. 1B). We also found that MenC-specific IgM levels were similar in groups immunized with different conjugate combinations, a result suggesting a similar level of B cell activation independent of the carrier (SI Ap- pendix,Fig.S1A). To exclude the possibility that we were seeing a T cell-independent response, we treated mice with CD4-specific blocking antibody during the interval between priming and boosting with MenC-CRM197. The excellent booster IgG response observed in mice treated with isotype control antibody was sig- nificantly reduced in mice treated with anti-CD4 (SI Appendix, Fig. S1B). The failure of MenC conjugates prepared with different carrier proteins to induce a booster IgG response suggested that perhaps these glycoconjugates
Load more

Recommended publications
  • Antimicrobial Glycoconjugate Vaccines: an Overview of Classic and Modern Approaches Cite This: Chem
    Chem Soc Rev View Article Online TUTORIAL REVIEW View Journal | View Issue Antimicrobial glycoconjugate vaccines: an overview of classic and modern approaches Cite this: Chem. Soc. Rev., 2018, 47, 9015 for protein modification Francesco Berti * and Roberto Adamo * Glycoconjugate vaccines obtained by chemical linkage of a carbohydrate antigen to a protein are part of routine vaccinations in many countries. Licensed antimicrobial glycan–protein conjugate vaccines are obtained by random conjugation of native or sized polysaccharides to lysine, aspartic or glutamic amino acid residues that are generally abundantly exposed on the protein surface. In the last few years, the structural approaches for the definition of the polysaccharide portion (epitope) responsible for the immunological activity has shown potential to aid a deeper understanding of the mode of action of glycoconjugates and to lead to the rational design of more efficacious and safer vaccines. The combination of technologies to obtain more defined carbohydrate antigens of higher purity and novel approaches for Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Received 12th June 2018 protein modification has a fundamental role. In particular, methods for site selective glycoconjugation like DOI: 10.1039/c8cs00495a chemical or enzymatic modification of specific amino acid residues, incorporation of unnatural amino acids and glycoengineering, are rapidly evolving. Here we discuss the state of the art of protein engineering with rsc.li/chem-soc-rev carbohydrates to obtain glycococonjugates vaccines and future perspectives. Key learning points (a) The covalent linkage with proteins is fundamental to transform carbohydrates, which are per se T-cell independent antigens, in immunogens capable of This article is licensed under a evoking a long-lasting T-cell memory response.
    [Show full text]
  • A Genome-Wide Shrna Screen Identifies GAS1 As a Novel Melanoma Metastasis Suppressor Gene
    Downloaded from genesdev.cshlp.org on October 5, 2021 - Published by Cold Spring Harbor Laboratory Press A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor gene Stephane Gobeil,1 Xiaochun Zhu,1 Charles J. Doillon,2 and Michael R. Green1,3 1Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA; 2Oncology and Molecular Endocrinology Research Center, CHUL’s Research Center, CHUQ, Laval University, Quebec City, Québec G1V 4G2, Canada Metastasis suppressor genes inhibit one or more steps required for metastasis without affecting primary tumor formation. Due to the complexity of the metastatic process, the development of experimental approaches for identifying genes involved in metastasis prevention has been challenging. Here we describe a genome-wide RNAi screening strategy to identify candidate metastasis suppressor genes. Following expression in weakly metastatic B16-F0 mouse melanoma cells, shRNAs were selected based upon enhanced satellite colony formation in a three-dimensional cell culture system and confirmed in a mouse experimental metastasis assay. Using this approach we discovered 22 genes whose knockdown increased metastasis without affecting primary tumor growth. We focused on one of these genes, Gas1 (Growth arrest-specific 1), because we found that it was substantially down-regulated in highly metastatic B16-F10 melanoma cells, which contributed to the high metastatic potential of this mouse cell line. We further demonstrated that Gas1 has all the expected properties of a melanoma tumor suppressor including: suppression of metastasis in a spontaneous metastasis assay, promotion of apoptosis following dissemination of cells to secondary sites, and frequent down-regulation in human melanoma metastasis-derived cell lines and metastatic tumor samples.
    [Show full text]
  • Glypican (Heparan Sulfate Proteoglycan) Is Palmitoylated, Deglycanated and Reglycanated During Recycling in Skin Fibroblasts
    Glycobiology vol. 7 no. 1 pp. 103-112, 1997 Glypican (heparan sulfate proteoglycan) is palmitoylated, deglycanated and reglycanated during recycling in skin fibroblasts Gudrun Edgren1, Birgitta Havsmark, Mats Jonsson and granules (for reviews, see Kjell6n and Lindahl, 1991; Bernfield Lars-Ake Fransson et al., 1992; David, 1993; Heinegard and Oldberg, 1993). Pro- teoglycans are classified according to the characteristic fea- Department of Cell and Molecular Biology, Faculty of Medicine, Lund University, Lund, Sweden tures or properties of the core protein and can appear in many 'To whom correspondence should be addressed at: Department of Cell and glycoforms giving rise to considerable structural variation and Downloaded from https://academic.oup.com/glycob/article/7/1/103/725516 by guest on 30 September 2021 Molecular Biology 1, POB 94, S-221 00, Lund, Sweden functional diversity. In general, the protein part determines the destination of the proteoglycan and interacts with other mol- Skin fibroblasts treated with brefeldin A produce a recy- ecules at the final location. The glycan part provides the overall cling variant of glypican (a glycosylphosphatidylinositol- bulk properties as well as binding sites for other gly- anchored heparan-sulfate proteoglycan) that is resistant to cosaminoglycans and many types of proteins, including matrix inositol-specific phospholipase C and incorporates sulfate proteins, plasma proteins, enzymes, anti-proteinases, growth and glucosamine into heparan sulfate chains (Fransson, factors, and cytokines. L.-A. et aL, Glycobiology, 5, 407-415, 1995). We have now Cultured human fibroblasts synthesize, deposit, and secrete investigated structural modifications of recycling glypican, 3 a variety of proteoglycans and have been used extensively to such as fatty acylation from [ H]palmitate, and degrada- investigate both their biosynthesis and functional properties tion and assembly of heparan sulfate side chains.
    [Show full text]
  • Glycoconjugates
    Background Information on Glycoconjugates Richard D. Cummings, Ph.D. Director, National Center for Functional Glycomics Professor Department of Surgery Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA 02114 Tel: (617) 735-4643 e-mail: [email protected] For General Reference On-Line See: Essentials of Glycobiology (2nd Edition) Varki, Cummings, Esko, Freeze, Stanley, Bertozzi, Hart and Etzler) http://www.ncbi.nlm.nih.gov/books/NBK1908/ Mammalian Cells are Covered with Glycoconjugates GLYCOSAMINOGLYCANS/ GLYCOPROTEINS PROTEOGLYCANS GLYCOLIPIDS NUCLEAR/CYTOPLASMIC GLYCOPROTEINS 2 Mammalian Glycoconjugates are Recognized by a Wide Variety of Specific Proteins GLYCAN-BINDING PROTEIN (GBP) GBP ANTIBODY TOXIN GBP GBP VIRUS 7 ANTIBODY GBP MICROBE TOXIN 3 Glycosylation Pathways 4 Glycosylation Pathways 5 Glycoconjugates, Which are Molecules Containing Sugars (Monosaccharides) Linked Within Them, are the Major Constituents of Animal Cell Membranes (Glycocalyx) and Secreted Material: See Different Classes of Glycoconjugates Below in Red Boxes PROTEOGLYCANS GLYCOSAMINOGLYCANS GLYCOSAMINOGLYCANS GLYCOPROTEINS GPI-ANCHORED GLYCOPROTEINS GLYCOLIPIDS outside Cell Membrane cytoplasm Essentials of Glycobiology, 3rd Edition CYTOPLASMIC GLYCOPROTEINS Chapter 1, Figure 6 Glycans are as Ubiquitous as DNA/RNA and Appear to Represent Greater Molecular Diversity 7 Big Picture: Nucleotide Sugars Connection of • UDP-Glc, • UDP-Gal, • UDP-GlcNAc, Glycoconjugate • UDPGalNAc, • UDP-GlcA, Biosynthesis • UDP-Xyl, • GDP-Man, • GDP-Fuc, to Intermediary • CMP-Neu5Ac used for synthesizing Metabolism glycoconjugates, e.g, glycoproteins & glycolipids 8 Important Topics to Consider 1. The different types of monosaccharides found in animal cell glycoconjugates 2. The different types of glycoconjugates and their differences, e.g. glycoproteins, glycolipids 3. The nucleotide sugars, glycosyltransferases, glycosidases, transporters, endoplasmic reticulum, and Golgi in terms of their roles in glycoconjugate biosynthesis and turnover 4.
    [Show full text]
  • Vasoactive Intestinal Peptide in Human Nasal Mucosa
    Vasoactive intestinal peptide in human nasal mucosa. J N Baraniuk, … , J H Shelhamer, M A Kaliner J Clin Invest. 1990;86(3):825-831. https://doi.org/10.1172/JCI114780. Research Article Vasoactive intestinal peptide (VIP), which is present with acetylcholine in parasympathetic nerve fibers, may have important regulatory functions in mucous membranes. The potential roles for VIP in human nasal mucosa were studied using an integrated approach. The VIP content of human nasal mucosa was determined to be 2.84 +/- 0.47 pmol/g wet weight (n = 8) by RIA. VIP-immunoreactive nerve fibers were found to be most concentrated in submucosal glands adjacent to serous and mucous cells. 125I-VIP binding sites were located on submucosal glands, epithelial cells, and arterioles. In short-term explant culture, VIP stimulated lactoferrin release from serous cells but did not stimulate [3H]glucosamine-labeled respiratory glycoconjugate secretion. Methacholine was more potent than VIP, and methacholine stimulated both lactoferrin and respiratory glycoconjugate release. The addition of VIP plus methacholine to explants resulted in additive increases in lactoferrin release. Based upon the autoradiographic distribution of 125I-VIP binding sites and the effects on explants, VIP derived from parasympathetic nerve fibers may function in the regulation of serous cell secretion in human nasal mucosa. VIP may also participate in the regulation of vasomotor tone. Find the latest version: https://jci.me/114780/pdf Vasoactive Intestinal Peptide in Human Nasal Mucosa James
    [Show full text]
  • Heparin/Heparan Sulfate Proteoglycans Glycomic Interactome in Angiogenesis: Biological Implications and Therapeutical Use
    Molecules 2015, 20, 6342-6388; doi:10.3390/molecules20046342 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Heparin/Heparan Sulfate Proteoglycans Glycomic Interactome in Angiogenesis: Biological Implications and Therapeutical Use Paola Chiodelli, Antonella Bugatti, Chiara Urbinati and Marco Rusnati * Section of Experimental Oncology and Immunology, Department of Molecular and Translational Medicine, University of Brescia, Brescia 25123, Italy; E-Mails: [email protected] (P.C.); [email protected] (A.B.); [email protected] (C.U.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-030-371-7315; Fax: +39-030-371-7747. Academic Editor: Els Van Damme Received: 26 February 2015 / Accepted: 1 April 2015 / Published: 10 April 2015 Abstract: Angiogenesis, the process of formation of new blood vessel from pre-existing ones, is involved in various intertwined pathological processes including virus infection, inflammation and oncogenesis, making it a promising target for the development of novel strategies for various interventions. To induce angiogenesis, angiogenic growth factors (AGFs) must interact with pro-angiogenic receptors to induce proliferation, protease production and migration of endothelial cells (ECs). The action of AGFs is counteracted by antiangiogenic modulators whose main mechanism of action is to bind (thus sequestering or masking) AGFs or their receptors. Many sugars, either free or associated to proteins, are involved in these interactions, thus exerting a tight regulation of the neovascularization process. Heparin and heparan sulfate proteoglycans undoubtedly play a pivotal role in this context since they bind to almost all the known AGFs, to several pro-angiogenic receptors and even to angiogenic inhibitors, originating an intricate network of interaction, the so called “angiogenesis glycomic interactome”.
    [Show full text]
  • Detection and Quantification of Antiborlies to the Extracellular Domain of PO During Experimental Allergic Neuritis
    Journal of the Neurological Sciences, 117 (1993) 197-205 197 © 1993 Elsevier Science Publishers B.V. All rights resetved 0022-SlOX/93/$06.00 JNS 04021 Detection and quantification of antiborlies to the extracellular domain of PO during experimental allergic neuritis J.J. Archelos a, K. Roggenbuck a, J. Schneider-Schaulies b, K.V. Toyka a and H.-P. Hartung a a Department of Neuro/ogy and Multiple Sc/erosis Research Group, Julius-Maximilians-Universität Würzburg, Josef-Schneider-Str. 11, D-8700 Würzburg, Germany, and b Institute of Virology and lmmunobio/ogy, Julius-Maximilians-Universität Würzburg, Versbacher Str. 7, D-8700 Würzburg, Germany (Received 13 August, 1992) (Revised, received 18 December, 1992) (Accepted 2 January, 1993) Key words: PO; Extracellular domain; Neuritis; GBS; Auto-antibodies Summary Quantification of the peripheral nerve myelin glycoprotein PO and antibodies to PO is difficult due to insolubility of PO in physiological solutions. We have overcome this problern by using the water-soluble recombinant form of the extracellular domain of PO (PO-ED) and describe newly developed assays which allow detection and quantitation of PO and antibodies to PO, in serum and cerebraspinal fluid (CSF). These sensitive and specific assays based on the ELISA technique were used to study humoral immune responses to PO during experimental autoimmune ("allergic") neuritis (EAN). In order to establish these tests, monoclonal antiborlies to different epitopes of rodent and human PO-ED were produced. A two-antibody sandwich-ELISA allowing quantitation of PO Oower detection Iimit of 0.5 ngjml or 30 fmoljml) and an antibody-capture ELISA (lower detection Iimit 1 ng specific antibody jml) to detect antiborlies to PO in serum and CSF were developed.
    [Show full text]
  • Protein C Product Monograph 1995 COAMATIC® Protein C Protein C
    Protein C Product Monograph 1995 COAMATIC® Protein C Protein C Protein C, Product Monograph 1995 Frank Axelsson, Product Information Manager Copyright © 1995 Chromogenix AB. Version 1.1 Taljegårdsgatan 3, S-431 53 Mölndal, Sweden. Tel: +46 31 706 20 00, Fax: +46 31 86 46 26, E-mail: [email protected], Internet: www.chromogenix.se COAMATIC® Protein C Protein C Contents Page Preface 2 Introduction 4 Determination of protein C activity with 4 snake venom and S-2366 Biochemistry 6 Protein C biochemistry 6 Clinical Aspects 10 Protein C deficiency 10 Assay Methods 13 Protein C assays 13 Laboratory aspects 16 Products 17 Diagnostic kits from Chromogenix 17 General assay procedure 18 COAMATIC® Protein C 19 References 20 Glossary 23 3 Protein C, version 1.1 Preface The blood coagulation system is carefully controlled in vivo by several anticoagulant mechanisms, which ensure that clot propagation does not lead to occlusion of the vasculature. The protein C pathway is one of these anticoagulant systems. During the last few years it has been found that inherited defects of the protein C system are underlying risk factors in a majority of cases with familial thrombophilia. The factor V gene mutation recently identified in conjunction with APC resistance is such a defect which, in combination with protein C deficiency, increases the thrombosis risk considerably. The Chromogenix Monographs [Protein C and APC-resistance] give a didactic and illustrated picture of the protein C environment by presenting a general view of medical as well as technical matters. They serve as an excellent introduction and survey to everyone who wishes to learn quickly about this field of medicine.
    [Show full text]
  • Vaccine Immunology Claire-Anne Siegrist
    2 Vaccine Immunology Claire-Anne Siegrist To generate vaccine-mediated protection is a complex chal- non–antigen-specifc responses possibly leading to allergy, lenge. Currently available vaccines have largely been devel- autoimmunity, or even premature death—are being raised. oped empirically, with little or no understanding of how they Certain “off-targets effects” of vaccines have also been recog- activate the immune system. Their early protective effcacy is nized and call for studies to quantify their impact and identify primarily conferred by the induction of antigen-specifc anti- the mechanisms at play. The objective of this chapter is to bodies (Box 2.1). However, there is more to antibody- extract from the complex and rapidly evolving feld of immu- mediated protection than the peak of vaccine-induced nology the main concepts that are useful to better address antibody titers. The quality of such antibodies (e.g., their these important questions. avidity, specifcity, or neutralizing capacity) has been identi- fed as a determining factor in effcacy. Long-term protection HOW DO VACCINES MEDIATE PROTECTION? requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells Vaccines protect by inducing effector mechanisms (cells or capable of rapid and effective reactivation with subsequent molecules) capable of rapidly controlling replicating patho- microbial exposure. The determinants of immune memory gens or inactivating their toxic components. Vaccine-induced induction, as well as the relative contribution of persisting immune effectors (Table 2.1) are essentially antibodies— antibodies and of immune memory to protection against spe- produced by B lymphocytes—capable of binding specifcally cifc diseases, are essential parameters of long-term vaccine to a toxin or a pathogen.2 Other potential effectors are cyto- effcacy.
    [Show full text]
  • Recent Progress in the Field of Neoglycoconjugate Chemistry
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/247838044 Recent progress in the field of neoglycoconjugate chemistry Article in Biomolecular concepts · May 2010 DOI: 10.1515/BMC.2010.007 CITATIONS READS 0 29 4 authors, including: Carmen Jiménez-Castells David Andreu University Pompeu Fabra University Pompeu Fabra 7 PUBLICATIONS 61 CITATIONS 318 PUBLICATIONS 8,765 CITATIONS SEE PROFILE SEE PROFILE Ricardo Gutiérrez Gallego University Pompeu Fabra 99 PUBLICATIONS 1,541 CITATIONS SEE PROFILE All in-text references underlined in blue are linked to publications on ResearchGate, Available from: David Andreu letting you access and read them immediately. Retrieved on: 29 August 2016 Article in press - uncorrected proof BioMol Concepts, Vol. 1 (2010), pp. 85–96 • Copyright ᮊ by Walter de Gruyter • Berlin • New York. DOI 10.1515/BMC.2010.007 Review Recent progress in the field of neoglycoconjugate chemistry Carmen Jime´nez-Castells1, Sira Defaus1, David type N-glycans) in recombinant human erythropoietin (EPO) Andreu1 and Ricardo Gutie´rrez-Gallego1,2,* (2) (Figure 1). Carbohydrate attachment to the backbone, usually occur- 1 Department of Experimental and Health Sciences, ring at the protein surface, entails not only modest-to-sub- Pompeu Fabra University, Barcelona Biomedical Research stantial structure alteration but also often the generation of Park, Dr. Aiguader 88, 08003 Barcelona, Spain differently glycosylated variants of a single gene product. 2 Pharmacology Research Unit, Bio-analysis group, Glycosylation has been extensively studied in eukaryotes Neuropsychopharmacology program, Municipal Institute of (3–6) and evidence is growing that in prokaryotes it is also Medical Research IMIM-Hospital del Mar, Barcelona more common than hitherto supposed (7, 8).
    [Show full text]
  • A Semisynthetic Glycoconjugate Provides Expanded Cross-Serotype Protection
    bioRxiv preprint doi: https://doi.org/10.1101/2021.07.29.454378; this version posted July 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae Paulina Kaplonek1,2,#, Ling Yao1,3, Katrin Reppe3, Franziska Voß4, Thomas Kohler4, Friederike Ebner5, Alexander Schäfer 6, Ulrike Blohm6, Patricia Priegue1, Maria Bräutigam1, Claney L. Pereira1, Sharavathi G. Parameswarappa1, Madhu Emmadi1, Petra Ménová1,† Martin Witzenrath3,7, Sven Hammerschmidt4, Susanne Hartmann5, Leif E. Sander3,7,*, Peter H. Seeberger1,2,* Affiliations 1 Max-Planck-Institute of Colloids and Interfaces, Department of Biomolecular Systems, Am Mühlenberg 1, 14476 Potsdam, Germany. 2 Freie Universität Berlin, Institute of Chemistry and Biochemistry, Arnimallee 22, 14195 Berlin, Germany. 3 Department of Infectious Diseases and Respiratory Medicine, Charité - Universitaetsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. 4 Department of Molecular Genetics and Infection Biology, Interfaculty Institute for Genetics and Functional Genomics, Center for Functional Genomics of Microbes, University of Greifswald, Felix-Hausdorff-Str. 8, 17489 Greifswald, Germany. 5 Institute of Immunology, Centre for Infection Medicine, Department of Veterinary Medicine, Freie Universität Berlin, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany. bioRxiv preprint doi: https://doi.org/10.1101/2021.07.29.454378; this version posted July 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Evaluation of Ion Mobility for the Separation of Glycoconjugate
    This is a repository copy of Evaluation of ion mobility for the separation of glycoconjugate isomers due to different types of sialic acid linkage, at the intact glycoprotein, glycopeptide and glycan level.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/126084/ Version: Accepted Version Article: Barroso, A, Giménez, E, Konijnenberg, A et al. (3 more authors) (2018) Evaluation of ion mobility for the separation of glycoconjugate isomers due to different types of sialic acid linkage, at the intact glycoprotein, glycopeptide and glycan level. Journal of proteomics, 173. pp. 22-31. ISSN 1874-3919 https://doi.org/10.1016/j.jprot.2017.11.020 (c) 2017, Elsevier Ltd. This manuscript version is made available under the CC BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/ Reuse Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item. Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ *Revised
    [Show full text]